Meyer M Samama
Overview
Explore the profile of Meyer M Samama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
693
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Halim A, Samama M, Mendell J
Thromb Res
. 2014 Sep;
134(4):909-13.
PMID: 25179520
Introduction: Edoxaban is an oral, once-daily direct factor Xa (FXa) inhibitor. Although rapidly cleared, strategies to reverse edoxaban-mediated effects on anticoagulation are needed in cases of excessive bleeding or emergency....
2.
Pernod G, Albaladejo P, Godier A, Samama C, Susen S, Gruel Y, et al.
Arch Cardiovasc Dis
. 2013 Jul;
106(6-7):382-93.
PMID: 23810130
Direct new oral anticoagulants (NOACs) - inhibitors of thrombin or factor Xa - are intended to be used largely in the treatment of venous thromboembolic disease or the prevention of...
3.
Mendell J, Lee F, Chen S, Worland V, Shi M, Samama M
J Cardiovasc Pharmacol
. 2013 Apr;
62(2):212-21.
PMID: 23615159
Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) and/or nonsteroidal anti-inflammatory...
4.
Samama M, Combe S, Conard J, Horellou M
Thromb Res
. 2011 Nov;
129(2):127-32.
PMID: 22047755
No abstract available.
5.
Gerotziafas G, Baccouche H, Sassi M, Galea V, Chaari M, Hatmi M, et al.
Thromb Res
. 2011 Oct;
129(1):101-3.
PMID: 22000405
No abstract available.
6.
Jeske W, Walenga J, Samama M, Hoppensteadt D, Mayuga M, Fareed J
Blood Coagul Fibrinolysis
. 2011 Feb;
22(3):206-10.
PMID: 21297455
Fondaparinux (Arixtra) is an antithrombin (AT)-dependent synthetic inhibitor of factor Xa (FXa). We undertook a study to determine the ramifications of varying levels of circulating AT on the pharmacologic activity...
7.
Samama M, Guinet C
Clin Chem Lab Med
. 2011 Feb;
49(5):761-72.
PMID: 21288169
With the introduction of new anticoagulant agents, there is a need for information on which coagulation tests are most suitable. These agents react differently to assays used to monitor older...
8.
Amin A, Girard F, Samama M
Thromb Haemost
. 2010 Sep;
104(5):955-61.
PMID: 20838741
In the US, ambulatory status is often a criterion for stopping prophylaxis for venous thromboembolism (VTE). In an analysis of the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial, ambulatory...
9.
Samama M, Kunitada S, Oursin A, Depasse F, Heptinstall S
Thromb Res
. 2010 Sep;
126(4):e286-93.
PMID: 20807664
Introduction: Edoxaban (the free base of DU-176b) is a new, oral direct Factor Xa inhibitor. This is the first study to compare the hemostatic response to edoxaban, ximelagatran, and dalteparin...
10.
Gerotziafas G, Dupont C, Spyropoulos A, Hatmi M, Samama M, Kiskinis D, et al.
Thromb Haemost
. 2009 Jul;
102(1):42-8.
PMID: 19572066
Vitamin K antagonists (VKA) treatment starts with co-administration of low-molecular-weight heparin (LMWH). The anticoagulation induced by the two drugs is still not well determined. In the present study we used...